SELLAS Life Sciences Group (SLS) Current Deferred Revenue: 2011-2021
Historic Current Deferred Revenue for SELLAS Life Sciences Group (SLS) over the last 1 years, with Mar 2021 value amounting to $900,000.
- SELLAS Life Sciences Group's Current Deferred Revenue was N/A to $900,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $900,000, marking a year-over-year change of. This contributed to the annual value of $5.6 million for FY2020, which is N/A change from last year.
- Latest data reveals that SELLAS Life Sciences Group reported Current Deferred Revenue of $900,000 as of Q1 2021, which was down 83.93% from $5.6 million recorded in Q4 2020.
- Over the past 5 years, SELLAS Life Sciences Group's Current Deferred Revenue peaked at $5.6 million during Q4 2020, and registered a low of $900,000 during Q1 2021.
- In the last 2 years, SELLAS Life Sciences Group's Current Deferred Revenue had a median value of $3.2 million in 2020 and averaged $3.2 million.